Nicotinic acetylcholine receptor α4 subunit gene polymorphism and attention deficit hyperactivity disorder

被引:56
作者
Kent, L
Middle, F
Hawi, Z
Fitzgerald, M
Gill, M
Feehan, C
Craddock, N
机构
[1] Univ Birmingham, Queen Elizabeth Psychiat Hosp, Dept Psychiat, Div Neurosci, Birmingham B15 2QZ, W Midlands, England
[2] Trinity Coll Dublin, Dept Psychiat, Dublin, Ireland
[3] Birmingham Childrens Hosp NHS Trust, Birmingham, W Midlands, England
基金
英国医学研究理事会;
关键词
attention deficit hyperactivity disorder; genetics; CHRNA4; association study;
D O I
10.1097/00041444-200103000-00007
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Attention deficit hyperactivity disorder (ADHD) is a highly heritable, common psychiatric disorder that presents in childhood and that probably involves several genes, There are several lines of evidence suggesting that the nicotinic system may be functionally significant in ADHD: (a) nicotine promotes the release of dopamine and has been shown to improve attention in adults with ADHD, smokers and non-smokers; (b) ADHD is a significant risk factor for early initiation of cigarette smoking in children; (c) maternal cigarette smoking appears to be a risk factor for ADHD; (d) animal studies in rats and monkeys also suggest that nicotine may be involved in attentional systems and locomotor activity; and (e) a central nicotinic agonist, ABT-418, improves attention in both monkeys and ADHD adults. The current study examined the or alpha4 receptor, one of the sites of action of ABT-418, A known Cfo1 polymorphism within the nicotinic acetylcholine or alpha4 receptor gene, CHRNA4, was studied in 70 ADHD parent-proband trios from an ongoing sample collection of children aged 6-12 with ADHD, according to DSM-IV criteria, Children with known major medical or psychiatric conditions or mental retardation (IQ < 70) were excluded from the study, The Transmission Disequilibrium Test demonstrated no evidence that variation at the nicotinic acetylcholine <alpha>4 receptor Cfo1 polymorphism influences susceptibility to ADHD (P > 0.35). The continuing sample collection will enable further study of other potential nicotinic system polymorphisms in ADHD in more powerful samples, Psychiatr Genet 11:37-40 (C) 2001 Lippincott Williams & Wilkins.
引用
收藏
页码:37 / 40
页数:4
相关论文
共 25 条
[1]  
ANGOLD A, 1995, PSYCHOL MED, V25, P739, DOI 10.1017/S003329170003498X
[2]   Lack of an association between a dopamine-4 receptor polymorphism and attention-deficit/hyperactivity disorder: genetic and brain morphometric analyses [J].
Castellanos, FX ;
Lau, E ;
Tayebi, N ;
Lee, P ;
Long, RE ;
Giedd, JN ;
Sharp, W ;
Marsh, WL ;
Walter, JM ;
Hamburger, SD ;
Ginns, E ;
Rapoport, JL ;
Sidransky, E .
MOLECULAR PSYCHIATRY, 1998, 3 (05) :431-434
[3]  
COOK EH, 1995, AM J HUM GENET, V56, P993
[4]   Linkage of a neurophysiological deficit in schizophrenia to a chromosome 15 locus [J].
Freedman, R ;
Coon, H ;
MylesWorsley, M ;
OrrUrtreger, A ;
Olincy, A ;
Davis, A ;
Polymeropoulos, M ;
Holik, J ;
Hopkins, J ;
Hoff, M ;
Rosenthal, J ;
Waldo, MC ;
Reimherr, F ;
Wender, P ;
Yaw, J ;
Young, DA ;
Breese, CR ;
Adams, C ;
Patterson, D ;
Adler, LE ;
Kruglyak, L ;
Leonard, S ;
Byerley, W .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1997, 94 (02) :587-592
[5]   EFFECTS OF PRENATAL NICOTINE EXPOSURE ON RAT STRIATAL DOPAMINERGIC AND NICOTINIC SYSTEMS [J].
FUNG, YK ;
LAU, YS .
PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR, 1989, 33 (01) :1-6
[6]   Confirmation of association between attention deficit hyperactivity disorder and a dopamine transporter polymorphism [J].
Gill, M ;
Daly, G ;
Heron, S ;
Hawi, Z ;
Fitzgerald, M .
MOLECULAR PSYCHIATRY, 1997, 2 (04) :311-313
[7]   Hyperlocomotion and indifference to cocaine and amphetamine in mice lacking the dopamine transporter [J].
Giros, B ;
Jaber, M ;
Jones, SR ;
Wightman, RM ;
Caron, MG .
NATURE, 1996, 379 (6566) :606-612
[8]  
LaHoste GJ, 1996, MOL PSYCHIATR, V1, P121
[9]   Transdermal nicotine effects on attention [J].
Levin, ED ;
Conners, CK ;
Silva, D ;
Hinton, SC ;
Meck, WH ;
March, J ;
Rose, JE .
PSYCHOPHARMACOLOGY, 1998, 140 (02) :135-141
[10]  
Milberger S, 1996, AM J PSYCHIAT, V153, P1138